Pazopanib and Statin-Induced Rhabdomyolysis

BACKGROUND: The VEGF inhibitor pazopanib is a widely used first-line therapy for the treatment of advanced renal cell carcinoma. Potential drug-drug interactions and toxicities may be underrecognized. CASE PRESENTATION: A 73-year-old woman with metastatic renal cell carcinoma on treatment with pazop...

Descripción completa

Detalles Bibliográficos
Autores principales: Logue, Jennifer M., Kiani, Bahram, Bitting, Rhonda L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731169/
https://www.ncbi.nlm.nih.gov/pubmed/29279698
http://dx.doi.org/10.1159/000481659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731169/
https://www.ncbi.nlm.nih.gov/pubmed/29279698
http://dx.doi.org/10.1159/000481659

Ejemplares similares